Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-08-11
2010-12-28
Angell, J. E (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07858590
ABSTRACT:
Described herein are compositions and methods for the treatment of Parkinson's disease (PD) and/or to protect dopaminergic nigrostriatal neuronal cell bodies from 6-OHDA-induced neurotoxicity in a mammal. In various embodiments of the invention, the dopaminergic neuron differentiation factor sonic hedgehog (Shh) and/or its downstream transcription factor target Gli-1 are used in connection with gene therapeutic techniques or direct peptide injection for the aforementioned indications. Kits useful in practicing the inventive method are also disclosed, as are animal models useful for studying various neurodegenerative conditions.
REFERENCES:
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5173414 (1992-12-01), Lebkowski et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5844079 (1998-12-01), Ingham et al.
patent: 6165747 (2000-12-01), Ingham et al.
patent: 6271363 (2001-08-01), Ingham et al.
patent: 6384192 (2002-05-01), Ingham et al.
patent: 6576237 (2003-06-01), Ingham et al.
patent: 6607913 (2003-08-01), Ingham et al.
patent: 6630148 (2003-10-01), Ingham et al.
patent: 7135454 (2006-11-01), Chimienti et al.
patent: 7138492 (2006-11-01), Miao et al.
patent: 2003/0054437 (2003-03-01), Ingham et al.
patent: 2003/0104995 (2003-06-01), Reilly
patent: 2003/0162698 (2003-08-01), Galdes et al.
patent: 2003/0186357 (2003-10-01), Ingham et al.
patent: 2004/0072345 (2004-04-01), Altaba et al.
patent: 2004/0092010 (2004-05-01), Altaba et al.
patent: WO92/01070 (1992-01-01), None
patent: WO93/03769 (1993-03-01), None
patent: WO97/00117 (1997-01-01), None
patent: WO99/04775 (1999-02-01), None
patent: WO03/070265 (2003-08-01), None
Akazawa et al., The Upregulated Expression of Sonic Hedgehog in Motor Neurons After Rat Facial Nerve Axotomy, The Journal of Neuroscience, (Sep. 8, 2004), pp. 7923-7930, 24(36).
Alzghoul et al., Ectopic Expression of IGF-I and Shh by Skeletal Muscle Inhibits Disuse-Mediated Skeletal Muscle Atrophy and Bone Osteopenia In Vivo, The FASEB Journal, (Jan. 2004), pp. 221-223, 18(1).
Bergstein et al., In Vivo Enhanced Expression of Patched Dampens the Sonic Hedgehog Pathway, Molecular Therapy, (Aug. 2002), pp. 258-264, 6(2).
Bezard et al., Sonic Hedgehog Is a Neuromodulator in the Adult Subthalamic Nucleus, The FASEB Journal, (Dec. 2003), pp. 2337-2338, 17(15).
Bhardwaj et al., Sonic Hedgehog Induces The Proliferation of Primitive Human Hematopoietic Cells Via BMP Regulation, Nature Immunology, (Feb. 2001), pp. 172-180, 2(2).
Bilang-Bleuel et al., Intrastriatal Injection of an Adenoviral Vector Expressing Glial-Cell-Line-Derived Neurotrophic Factor Prevents Dopaminergic Neuron Degeneration and Behavioral Impairment in a Rat Model of Parkinson Disease, Proceedings of the National Academy of Sciences, USA, (Aug. 1997), pp. 8818-8823, 94.
Bjorklund et al., Towards a Neuroprotective Gene Therapy for Parkinson's Disease: Use of Adenovirus, AAV and Lentivirus Vectors For Gene Transfer of GDNF to the Nigrostriatal System in the Rat Parkinson Model, Brain Research, (Dec. 15, 2000), pp. 82-98, 886(1-2).
Bohn, M.C., A Commentary on Glial Cell Line-Derived Neurotrophic Factor (GDNF). From a Glial Secreted Molecule to Gene Therapy, Biochemical Pharmacology, (Jan. 15, 1999), pp. 135-142, 57(2).
Cass, W.A., GDNF Selectively Protects Dopamine Neurons Over Serotonin Neurons Against the Neurotoxic Effects of Methamphetamine, the Journal of Neuroscience, (Dec. 15, 1996), pp. 8132-8139, 16(24).
Castro et al., Gene Therapy for Parkinson's Disease: Recent Achievements and Remaining Challenges, Histology and Histopathology, (2001), pp. 1225-1238, 16.
Choi-Lundberg et al., Dopaminergic Neurons Protected From Degeneration by GDNF Gene Therapy, Science, (Feb. 7, 1997), 275.
Connor et al., Differential Effects of Glial Cell Line-Derived Neurotrophic Factor (GDNF) in the Striatum and Substantia Nigra of the Aged Parkinsonian Rat, (1999), pp. 1936-1951, 6.
Connor et al., Glial Cell Line-Derived Neurotrophic Factor (GDNF) Gene Delivery Protects Dopaminergic Terminals From Degeneration, Experimental Neurology, (May 2001), pp. 83-95, 169(1).
Dass et al., Behavioural and Immunohistochemical Changes Following Supranigral Administration of Sonic Hedgehog in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Common Marmosets, Neuroscience, (2002), pp. 99-109, 114(1).
Eberhardt et al., Protection by Synergistic Effects of Adenovirus-Mediated X-Chromosome-Linked Inhibitor of Apoptosis and Glial Cell Line-Derived Neurotrophic Factor Gene Transfer in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease, The Journal of Neuroscience, (Dec. 15, 2000), pp. 9123-9134, 20(24).
Edwards et al., Sonic Hedgehog Gene-Enhanced Tissue Engineering for Bone Regeneration, Gene Therapy, (Jan. 2005), pp. 75-86, 12(1).
Gill et al., Direct Brain Infusion of Glial Cell Line-Derived Neurotrophic Factor in Parkinson Disease, Nature Medicine, (May 2003), pp. 589-595, 9(5).
Grande et al., Stem Cells As Platforms for Delivery of Genes to Enhance Cartilage Repair, The Journal of Bone and Joint Surgery American, (2003), pp. 111-116, 85 (A Suppl).
Hurtado-Lorenzo et al., Adenovirus-Mediated Gene Transfer of Shh, GLI-1 and Nurr1 in a Rat Model of Parkinson's Disease, Society of Neuroscience Abstracts, (2000), Abstract No. 666.17.
Hurtado-Lorenzo et al., Differentiation and Transcription Factor Gene Therapy in Experimental Parkinson's Disease: Sonic Hedgehog and Gli-1, But Not Nurr-1, Protect Nigrostriatal Cell Bodies From 6-OHDA-Induced Neurodegeneration, Molecular Therapy, (Sep. 2004), pp. 507-524, 10(3).
Kirik et al., Long-Term rAAvV-Mediated Gene Transfer of GDNF in the Rat Parkinson's Model: Intrastriatal But Not Intranigral Transduction Promotes Functional Regeneration in the Lesioned Nigrostriatal System, the JournalOf Neuroscience, (Jun. 15, 2000), pp. 4686-4700, 20(12).
Kordower et al., Clinicopathological Finding Following Intraventricular Glial-Derived Neurotrophic Factor Treatment in a Patient With Parkinson's Disease, Annals of Neurology, (Sep. 1999), pp. 419-424, 46(3).
Kordower et al., Neurodegeneration Prevented by Lentiviral Vector Delivery of GDNF in Primate Models of Parkinson's Disease, Science, (Oct. 27, 2000), pp. 767-773, 290.
Kubo et al., Hedgehog Signaling Pathway is a New Therapeutic Target for Patients With Breast Cancer, Cancer Research, (Sep. 1, 2004), pp. 6071-6074, 64.
Kusano et al., Sonic Hedgehog Induces Arteriogenesis in Diabetic Vasa Nervorum and Restores Function in Diabetic Neuropathy, Arteriosclerosis Thrombosisand Vascular Biology, (2004), pp. 2102-2107, 24.
Lowenstein et al., Neuronal-Specific Expression of Gli-1 is Neuroprotective in Experimental Parkinson's Disease, Without an Increase in Efficacy When Compared to a Pancellular Promoter, Society for Neuroscience Abstracts, (2003), Abstract No. 451.1.
Miao et al., Sonic Hedgehog Promotes the Survival of Specific CNS Neuron Populations and Protects These Cells From Toxic Insult In Vitro, The Journal of Neuroscience, (Aug. 1, 1997), pp. 5891-5899, 17(15).
Nutt et al., Randomized, Double-Blind Trial of Glial Cell Line-Derived Neurotrophic Factor (GDNF) in PD, Neurology, (Jan. 14, 2003), pp. 69-73, 60(1).
Pola et al., Postnatal Recapitulation of Embryonic Hedgehog Pathway in Response to Skeletal Muscle Ischemia, Circulation, (2003), pp. 479-485, 108.
Suwelack et al., Neuronal Expression of the Transcription Factor Gli1 Using the Tα1 α-Tublin Promoter Is Neuroprotective in an Experimental Model of Parkinson's Disease, Gene Therapy, (2004), pp. 1742-1752, 11.
Castro Maria
Lowenstein Pedro
Angell J. E
Cedars-Sinai Medical Center
Davis , Wright, Tremaine, LLP
Levy Seth D.
LandOfFree
Treatment of parkinson's disease and related disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of parkinson's disease and related disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of parkinson's disease and related disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4227072